Venatorx Pharmaceuticals today announced that it has two data presentations at IDWeek 2020, which is taking place virtually, starting today through October 25, 2020.

With over 25 years of biopharmaceutical industry experience, including multiple product and line extension launches, Mr. Sargent will be responsible for designing and executing Venatorx’s commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.

The study met its primary objective, demonstrating that the cefepime-taniborbactam combination treatment was safe and well tolerated among healthy Chinese volunteers with key pharmacokinetics parameters indicating no detectable signal of ethnic differences.

Venatorx Pharmaceuticals has been awarded a contract by NIAID to advance a novel series of Penicillin Binding Protein (PBP) Inhibitors targeting multi-drug resistant (MDR) Acinetobacter baumannii through Phase 1 clinical testing.

Venatorx Pharmaceuticals was named one of the “2020 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.

Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133).

Everest Medicines published the results in a paper entitled, “In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime, against MDR Gram-negative bacterial isolates from China”, which was published in the March 2020 issue of the Journal of Antimicrobial Chemotherapy.